LGM Pharma reported strong growth in 2022 in both its active pharmaceutical ingredient (API) division and its new contract development and manufacturing organization (CDMO) division. 

LGM acquired its CDMO division in 2020, with full operational integration accomplished in late 2021 for commercial manufacturing and for the two newly-created CDMO service segments, Analytical Testing Services (ATS) and Drug Product Research & Development (R&D).

According to the company, strong demand for these service offerings led to 49 ATS and R&D projects booked in 2022, achieving 150% of sales budget in the first full year of operations for these new service segments.

Demand in 2022 also remained strong for LGM Pharma’s established API Services division, with over 300 unique APIs delivered and 1,700-plus imports handled for clients.

In addition, robust customer demand fueled strong growth and investment in the CDMO division’s service segments, which provide analytical testing; method development and validation; formulation development; clinical trial material production and testing; stability studies; regulatory submissions; commercial manufacturing and more.

The CDMO division works with multiple dosage forms including oral solid dosages, oral disintegrating tablets, powders, liquids, suspensions, semi-solids and suppositories.

“The strong start posted by our CDMO business reflects our company-wide commitment to supporting customer needs with quality-assured, customer-centric strategies, said Prasad Raje, CEO of LGM Pharma. “These strategies are designed to increase speed and flexibility, reduce supply chain risks and improve access to high-quality drug products and APIs. We established the CDMO division to focus on the unmet needs of small to mid-size biopharma firms and are especially proud of the demonstrated speed, agility, and flexibility we employ to meet their distinctive needs.”

Raje added, “We look forward to continuing strong growth in our CDMO division, where our multiple US-based facilities and experienced technical staff are well-positioned to help companies advance their products through successful commercialization.”